, Human papillomavirus and cervical cancer, The Lancet, vol.370, issue.9590, pp.890-907, 2007.
DOI : 10.1016/S0140-6736(07)61416-0
, Efficacy of Vaccination against HPV Infections to Prevent Cervical Cancer in France: Present Assessment and Pathways to Improve Vaccination Policies, PLoS ONE, vol.29, issue.3, 2012.
DOI : 10.1371/journal.pone.0032251.s014
URL : https://hal.archives-ouvertes.fr/hal-00678652
, Estimation of vaccination coverage in France through the Permanent Beneficiaries Sample (EGB): exemple of measles, hepatitis B and human paillomavirus vaccination, Bull Epidemiol Hebd, vol.89, pp.72-76, 2013.
, A Contribution to the Mathematical Theory of Epidemics, Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, vol.115, issue.772, pp.700-721, 1927.
DOI : 10.1098/rspa.1927.0118
, A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus, Human Vaccines & Immunotherapeutics, vol.19, issue.11, 2013.
DOI : 10.1016/j.vaccine.2007.04.070
URL : https://hal.archives-ouvertes.fr/hal-00862596
, Deterministic modelling for transmission of Human Papillomavirus 6/11: impact of vaccination, Mathematical Medicine and Biology, vol.31, issue.2
DOI : 10.1093/imammb/dqt001
, Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program, BMC Infectious Diseases, vol.7, issue.3, pp.140-150, 2013.
DOI : 10.1071/SH09137
, Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule, Human Vaccines, vol.60, issue.12, pp.1374-86, 2011.
DOI : 10.4161/hv.5.10.9518